Multiple Myeloma Linked to Higher Risk for Hematologic Second Cancers

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

THURSDAY, April 30, 2026 -- Patients with multiple myeloma (MM) have a distinct pattern of second primary malignancy (SPM), with a markedly increased risk of hematologic SPMs, according to a review published online April 6 in Frontiers in Oncology.

Yingjie Tian, from Guang'anmen Hospital in Beijing, and colleagues conducted a systematic review to examine the risk for SPMs among individuals with MM. Standardized incidence ratios (SIRs) were used to compare SPM risks in patients with MM to the risks of those in the general population. A total of 15 studies, with 279,894 patients with MM, met the inclusion criteria.

The researchers found that the overall risks for SPMs and solid tumors were not significantly elevated compared with those in the general population. A marked elevation was seen in the risk for hematologic SPMs (SIR, 2.91). For several malignancies, higher risks were seen, including for non-Hodgkin lymphoma, myelodysplastic syndromes, acute myeloid leukemia, mesothelioma, skin cancer, melanoma, endocrine tumors, and thyroid cancer. For chronic lymphocytic leukemia, head and neck cancer, tracheal/bronchial/lung cancer, bladder cancer, and breast cancer, reduced risks were seen. No meaningful variation was seen by diagnostic period, latency, age, or sex in subgroup analyses.

"These findings underscore the distinctive SPM profile in patients with MM and support the need for tumor-specific surveillance strategies," the authors write. "Monitoring should place particular emphasis on hematologic SPMs, as well as on key solid tumors such as skin cancer, melanoma, endocrine malignancies, thyroid cancer, and mesothelioma."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-05-01 02:14

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords